Dermata Therapeutics, Inc. filed a Form 8-K on October 29, 2026, announcing enrollment of the first participant in a clinical trial evaluating Tome Clearing Treatment, its once-weekly acne treatment.

Key Highlights

  • First participant enrolled: The company announced enrollment of the first participant in a clinical trial evaluating Tome Clearing Treatment in participants with acne.
  • Treatment description: Tome Clearing Treatment is described in the filing as the company's once-weekly acne treatment.
  • Planned launch timing: According to the filing, the company expects to launch Tome Clearing Treatment as its second commercial product in the first half of 2027.
  • Exchange listing: Dermata Therapeutics common stock (par value $0.0001 per share) trades on The Nasdaq Capital Market under the symbol DRMA (NASDAQ:DRMA).
  • Signatory: The filing was signed by Gerald T. Proehl, Chief Executive Officer, dated October 29, 2026.

Dermata Therapeutics Reports First Enrollment in Tome Clearing Treatment Clinical Trial

Dermata Therapeutics, Inc. (NASDAQ:DRMA) disclosed in an October 29, 2026, Form 8-K filing that it had enrolled the first participant in a clinical trial for Tome Clearing Treatment. According to the filing, Tome Clearing Treatment is the company's once-weekly acne treatment, and the trial is evaluating it in participants with acne. The press release announcing this enrollment was issued on what the filing text states as October 29, 2027, though the filing itself is dated October 29, 2026.

The company disclosed that it expects to launch Tome Clearing Treatment as its "second commercial product in the first half of 2027." The filing does not provide additional detail on trial design, endpoints, participant count, or site locations. Dermata Therapeutics is incorporated in Delaware and headquartered at 3525 Del Mar Heights Rd., #322, San Diego, CA 92130.

The filing notes that statements regarding anticipated product launches, timing, and commercial expectations are "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995, and that actual results could "differ materially and adversely" from those implied by such statements. The company directs readers to the Risk Factors section of its Annual Report on Form 10-K and subsequent regulatory filings for a discussion of relevant risks and uncertainties.

What Was Disclosed

Dermata Therapeutics filed a Form 8-K on October 29, 2026, reporting the enrollment of the first participant in a clinical trial for its once-weekly Tome Clearing Treatment acne product, with an expected commercial launch in the first half of 2027.